头孢菌素药物市场- 依代（第一、第二）、适应症（呼吸道、泌尿道感染、性传染感染、胃肠道感染）、给药途径（口服、肠胃外、局部）、型式（仿製药、品牌）、配销通路、全球预测 2024 - 2032 年

在领先製药公司越来越多的产品核准和临床试验的推动下，2024 年至 2032 年间，全球头孢菌素药物市场规模的复合年增长率将超过 3.1%。

为了重点对抗细菌感染和解决新出现的抗生素抗药性，各公司正大力投资头孢菌素药物的研发。例如，2023年7月，Allecra Therapeutics揭露了向美国食品药物管理局（FDA）提交的抗生素头孢吡肟/恩美唑巴坦联合使用的新药申请（NDA）。该组合包括头孢吡肟（第四代头孢菌素）和恩美唑巴坦（一种专有的 β-内酰胺酶抑制剂）。

这些努力导致新配方获得批准并扩大了现有药物的适应症，推动了市场成长。此外，正在进行的探索头孢菌素治疗多种感染功效的临床试验进一步刺激了需求。随着医疗保健提供者寻求有效的治疗方案，信誉良好的公司提供的头孢菌素药物的供应量不断增加，突显了它们在应对与传染病相关的全球健康挑战方面的重要性。

整个头孢菌素药品产业根据产生、给药途径、类型、配销通路和地区进行分类。

从 2024 年到 2032 年，第二代头孢菌素细分市场将出现显着的复合年增长率。由于其穿透组织和对抗抗药性菌株的能力有所提高，第二代头孢菌素正在成为医疗保健专业人员的首选。随着细菌感染盛行率持续上升，抗生素抗药性构成重大挑战，对第二代头孢菌素药物的需求可能会持续成长，进而塑造医药市场的模式。

2024年至2032年，皮肤和软组织感染领域的头孢菌素类药物市场份额将呈指数级增长。头孢菌素抗生素通常用于治疗金黄色葡萄球菌和化脓性链球菌等细菌病原体引起的 SSTI。它们对这些病原体的广谱活性和功效使其成为治疗 SSTI 的基石。由于人口老化和抗药性细菌传播等因素的推动，全球SSTI发生率持续上升，对头孢菌素类药物的需求仍然强劲。

到2032年，亚太地区头孢菌素药物市场将占据主导地位。头孢菌素因其对各种细菌病原体的功效而成为该地区广泛使用的抗生素。此外，该地区不断扩大的医疗基础设施和改善医疗服务的可近性也有助于增加使用量。随着亚太地区应对传染病挑战，对头孢菌素药物的需求可能会继续呈上升趋势，从而塑造该地区的製药格局。例如，2023 年 3 月，国有政府製药实体基本药物有限公司 (EDCL) 在其博古拉工厂内建立了头孢菌素部门，以实现孟加拉国药品生产的自给自足。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 细菌感染的发生率增加
    • 加强抗生素开发合作
    • 越来越关注仿製药
  • 产业陷阱与挑战
    • 抗生素抗药性日益普遍
    • 其他抗生素的激烈竞争
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按世代，2018 - 2032

• 主要趋势
• 第一代头孢菌素
• 第二代头孢菌素
• 第三代头孢菌素
• 第四代头孢菌素
• 第五代头孢菌素

第 6 章：市场估计与预测：按指标划分，2018 年 - 2032 年

• 主要趋势
• 呼吸道感染
• 泌尿道感染（UTI）
• 皮肤和软组织感染
• 性传染感染（STI）
• 胃肠道感染
• 其他适应症

第 7 章：市场估计与预测：按管理途径，2018 年 - 2032 年

• 主要趋势
• 口服
• 注射用
• 专题

第 8 章：市场估计与预测：按药物类型，2018 - 2032

• 主要趋势
• 品牌化
• 通用的

第 9 章：市场估计与预测：按配销通路划分，2018 年 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 10 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 11 章：公司简介

• AbbVie Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

Global Cephalosporin Drugs Market Size will witness over 3.1% CAGR between 2024 and 2032, propelled by the increasing number of product approvals and clinical trials conducted by leading pharmaceutical companies.

With a focus on combating bacterial infections and addressing emerging antibiotic resistance, companies are investing heavily in the research and development of cephalosporin drugs. For instance, in July 2023, Allecra Therapeutics disclosed the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for a combination antibiotic, cefepime/enmetazobactam. This combination includes cefepime, a fourth-generation cephalosporin, and enmetazobactam, a proprietary beta-lactamase inhibitor.

These efforts have resulted in the approval of new formulations and expanded indications for existing drugs, driving market growth. Moreover, ongoing clinical trials exploring the efficacy of cephalosporins in treating a wide range of infections further fuel demand. As healthcare providers seek effective treatment options, the rising availability of cephalosporin drugs from reputable companies underscores their importance in addressing global health challenges related to infectious diseases.

The overall Cephalosporin Drugs Industry is classified based on the generation, route of administration, type, distribution channel, and region.

The second generation cephalosporin segment will register a significant CAGR from 2024 to 2032. These antibiotics offer enhanced efficacy against a broad spectrum of bacterial infections, including respiratory and urinary tract infections. With their improved ability to penetrate tissues and combat resistant strains, second-generation cephalosporins are becoming a preferred choice for healthcare professionals. As the prevalence of bacterial infections continues to rise and antibiotic resistance poses a significant challenge, the demand for second-generation cephalosporin drugs could continue growing, shaping the landscape of the pharmaceutical market.

The cephalosporin drugs market share from the skin and soft tissue infection segment will witness an exponential growth rate from 2024-2032. Cephalosporin antibiotics are commonly prescribed to treat SSTIs caused by bacterial pathogens such as Staphylococcus aureus and Streptococcus pyogenes. Their broad-spectrum activity and efficacy against these pathogens make them a cornerstone in the treatment of SSTIs. As the incidence of SSTIs continues to rise globally, driven by factors such as aging populations and the spread of antibiotic-resistant bacteria, the demand for cephalosporin drugs remains robust.

Asia Pacific cephalosporin drugs market will dominate the market share through 2032. Factors such as population growth, increasing urbanization, and a rising incidence of bacterial infections are driving this demand. Cephalosporins are widely prescribed antibiotics in the region due to their efficacy against various bacterial pathogens. In addition, the region's expanding healthcare infrastructure and improving access to medical services contribute to increased usage. As Asia Pacific grapples with infectious disease challenges, the demand for cephalosporin drugs could continue its upward trajectory, shaping the pharmaceutical landscape in the region. For instance, in March 2023, the Essential Drugs Company Limited (EDCL), a state-owned government pharmaceuticals entity, established a Cephalosporin Unit within its Bogura plant to achieve self-sufficiency in drug manufacturing in Bangladesh.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of bacterial infections
    • 3.2.1.2 Growing collaborations for development of antibiotics
    • 3.2.1.3 Increasing focus on generic medications
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Increasing prevalence of antibiotic resistance
    • 3.2.2.2 High competition from other antibiotics
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Generation, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 First generation cephalosporins
• 5.3 Second generation cephalosporins
• 5.4 Third generation cephalosporins
• 5.5 Fourth generation cephalosporins
• 5.6 Fifth generation cephalosporins

Chapter 6 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Respiratory infections
• 6.3 Urinary tract infections (UTIs)
• 6.4 Skin and soft tissue infections
• 6.5 Sexually transmitted infections (STIs)
• 6.6 Gastrointestinal infections
• 6.7 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral
• 7.4 Topical

Chapter 8 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Branded
• 8.3 Generic

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacy
• 9.3 Retail pharmacy
• 9.4 Online pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Bristol-Myers Squibb Company
• 11.3 Eli Lilly and Company
• 11.4 F. Hoffmann-La Roche Ltd.
• 11.5 Merck & Co., Inc.
• 11.6 Mylan N.V.
• 11.7 Novartis AG
• 11.8 Pfizer Inc.
• 11.9 Sanofi
• 11.10 Sun Pharmaceutical Industries Ltd.
• 11.11 Teva Pharmaceutical Industries Ltd.